Literature DB >> 26104249

Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy. A randomized, controlled trial.

Samuel Delgado De Pasquale1, Rodrigo Velarde1, Osvaldo Reyes2, Kerima De La Ossa1.   

Abstract

Hydralazine and labetalol for intravenous use are equally effective in the management of hypertensive crisis in pregnant patients (24weeks or more) with severe hypertensive disorders of pregnancy, showing a similar frequency of adverse effects in both groups.
Copyright © 2013 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hydralazine; Hypertensive crisis; Labetalol; Persistent hypertension; Severe hypertensive disorders of pregnancy

Year:  2013        PMID： 26104249     DOI： 10.1016/j.preghy.2013.08.001

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN： 2210-7789            Impact factor:   2.899


  3 in total

Review 1.  Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials.

Authors:  Kannan Sridharan; Reginald P Sequeira
Journal:  Br J Clin Pharmacol       Date:  2018-07-08       Impact factor: 4.335

2.  Comparison of Hydralazine and Labetalol to lower severe hypertension in pregnancy.

Authors:  Ayesha Khan; Sajida Hafeez; Farah Deeba Nasrullah
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

3.  Comparison of Efficacy and Safety of Intravenous Labetalol Versus Hydralazine for Management of Severe Hypertension in Pregnancy.

Authors:  Purvi Patel; Deepika Koli; Nandita Maitra; Tosha Sheth; Palak Vaishnav
Journal:  J Obstet Gynaecol India       Date:  2017-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.